Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Drug Profile

Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts

Alternative Names: Anti-TNF therapy - Numab/Tillotts; Antibody-based inflammatory bowel disease therapeutics - Numab/Tillotts; TNF-alpha blockers - Numab/Tillotts; TNF-α inhibitor antibodies- Numab/Tillotts; Tumour necrosis factor-alpha blockers - Numab/Tillotts

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Numab
  • Developer Numab; Tillotts Pharma
  • Class Antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 09 Jun 2015 TNF-α inhibitor antibodies licensed to Tillotts Pharma worldwide for the treatment of inflammatory bowel disease
  • 09 Jun 2015 Early research in Inflammatory bowel disease in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top